Copperfield Media presents Utah Cann: Utah’s Cannabis Conference & Expo, taking place at Utah State Fairpark on May 10-11 featuring over 50 exhibitors from the cannabis industry, CBD suppliers, software and technology, agriculture, advocacy groups, legal and more. The conference will also feature over 30 cannabis experts on the national scale to speak to attendees about the latest topics related to the industry.
Copperfield Media is proud to bring Utah Cann to the Utah State Fairpark for the second installment of the conference. Last October, Utah citizens voted in favor of Prop 2, Utah’s medical cannabis initiative, opening the door for patient relief and also for the business opportunities worth hundreds of millions to Utah. Utah Cann will give the people of Utah an opportunity to learn how they will be able to consume medical cannabis in the future, as well as learn about other derivatives of hemp and cannabis plants, such as cannabidiol (CBD) which is legal for consumption in all 50 states. Furthermore, the exhibitors and speakers will showcase their businesses and ventures and provide insights on how to thrive in the cannabis industry.
Ticket prices for the two day event range from $20 to $60 and are available for purchase on UtahCann.com. Silicon Slopes Members are entitled to a 25% discount until the night before the show May 09, 2019
Tickets purchased online can be redeemed at the event via mobile phone or printed at home. There will be day-of-event tickets available, though prices will increase at the door.
“We’ve assembled a very strong and accessible panel of cannabis experts from across the state,” said John Saltas, founder of Copperfield Media, host and sponsor of the Utah Cann medical cannabis conference. “Conference attendees will walk away from the All-Star discussions more informed and enlightened about the cannabis industry and legislation than ever before—especially the new choices before them regarding their personal health.”
About Utah Cann
For an excellent perspective on the quality of our speakers, please enjoy reading the following article which was published in the initial Utah Cannabis Magazine authored by Utah Cannabis Association executive director Thomas Paskett...
Balancing Regulation with Compassion
By Thomas Paskett
Utah is experiencing an exciting time with the opening of the legal and social doors to the medical, economic, and scientific potentials of the long misunderstood and maligned cannabis plant. Last year, Utah voters approved Proposition 2, sending a clear message to our government that We The People want to have medical cannabis available as a treatment option for a variety of health conditions. Although our legislature disregarded the clear will of the people with a special session, replacing Prop 2 with HB 3001, the door kicked open by voters could not be closed again. Medical cannabis is here to stay.
For all that has been said to criticize HB 3001 the fact remains that it has solidified the presence of a medical cannabis program in Utah. Making medical cannabis the law of the land made it nearly impossible for legislators to walk back their endorsement of medical cannabis as a legitimate option for the treatment of a variety of medical conditions. But let me be clear: HB 3001 is far from perfect. Policy makers, medical professionals and the entrepreneurs that hope to participate in the program are going to have to work hard to find the delicate balance that needs to be struck between sensible regulation and compassion. The battle to bring medical cannabis to Utah has been won; our current fight is to ensure that our government doesn’t overregulate the industry into the ground.
The state agencies tasked with promulgating the rules that will govern Utah’s medical cannabis program–the Department of Agriculture and Food and the Department of Health–are facing the difficult mandate of writing rules that conform to the new state law, while still creating a viable framework of regulations in which businesses can turn a profit and patients can afford their medicine. The relationship between patients and businesses is one that must be symbiotic in order for the entire program to succeed. After all, if businesses have to charge outrageous prices just to be able to keep up with the costs of staying within the law, patients will be forced to return to the black market to obtain their relief or forgo access to medical cannabis altogether. In such a scenario, businesses and patients will be harmed and Utah’s government will have no one to blame but itself.
Perhaps the most difficult area of the law for the private sector to contend with will likely be those provisions governing the retail side of the industry. Medical cannabis pharmacies, of which the state will initially only allow seven, have significant financial obstacles to viability. On top of hefty licensing and annual renewal fees, the steep cost of having at least one pharmacist on location during business hours, being forbidden from selling any FDA approved cannabis drugs (a prohibition as strange and irrational as outright prohibition itself), and the myriad other financial obligations that come with running a business, Utah’s medical cannabis pharmacies will be in competition with the state’s “central fill” model.
The central fill concept is the other part (the first part being the seven private pharmacies) of Utah’s unique dual-track system of distribution that is supposed to set up a state-run “hub” for medical cannabis products to be stored at before being shipped by currier to some 13 local health department offices around the state for pickup by patients. Although Utah’s law requires that the prices set for medical cannabis products being sold from the central fill facility must be “within 10% of the average price for the product among the operational medical cannabis pharmacies” the state can still undercut the prices of private pharmacies. Such a mechanism in a market specifically established for patients is not only antithetical to the free market but it makes patients the pawns of an overreaching government’s attempts to maintain a level of control over a substance it never should’ve had to begin with.
As stated above, HB 3001 is far from perfect, but a good start to making it better would be to drop the central fill concept from the law and expand the number of licenses for medical cannabis pharmacies. More pharmacies will mean a broader geographic spread of locations where patients can purchase their medicine. And removing the central fill model from the equation will ensure that the market is driven primarily by the industry and the patients it relies upon, rather than government bureaucracy. If Utah wishes to maintain its reputation for being business friendly and compassionate, it must do a better job of facilitating a viable medical cannabis market in which businesses can make money and patients can purchase affordable medicine.